Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial).

Frontiers in oncology·2026
Same author

Multidisciplinary Consensus Statement for Appropriate Evaluation and Workup of Sinonasal Masses.

JAMA otolaryngology-- head & neck surgery·2026
Same author

Clinical and economic burden of recurrence among older patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Journal of managed care & specialty pharmacy·2026
Same author

Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial.

Nature communications·2026
Same author

Enfortumab vedotin plus pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: results from EV-202 cohort 9.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

相关实验视频

Updated: Jul 25, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K

化学抗原受体T细胞治疗固体瘤的治疗方法

Jeremiah A Wala1, Glenn J Hanna1

  • 1Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building 2nd Floor, Room 2-140, Boston, MA 02215, USA.

Hematology/oncology clinics of North America
|June 23, 2023
PubMed
概括

化学抗原受体 (CAR) T细胞疗法在固体瘤中显示出前景. 克服瘤障碍和免疫抑制等挑战是推动CAR T细胞治疗各种癌症的关键.

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 细胞工程 细胞工程

背景情况:

  • 化学抗原受体 (CAR) T细胞疗法已经彻底改变了某些血液性恶性瘤.
  • 它的转化到固体瘤面临着重大的生物和技术障碍.

研究的目的:

  • 审查目前CAR T细胞治疗固体瘤的现状.
  • 突出现场挑战和新出现的解决方案.
  • 总结正在进行的临床试验.

主要方法:

  • 在固体瘤中使用CAR T细胞治疗的文献综述.
  • 讨论患者选择,临床管理和障碍.
  • 综合生物学和细胞工程进步的概述.
  • 对各种癌症类型的临床试验数据的摘要.

主要成果:

  • 存在重大挑战,包括物理/分子障碍,免疫抑制瘤微环境和向抗原识别.
  • 合成生物学和细胞工程提供了新的策略来提高CAR T细胞的疗效.
  • 许多临床试验正在研究各种固体瘤的CAR T细胞疗法.

结论:

关键词:
抗原选择抗原选择细胞工程 细胞工程化学抗原受体的化学抗原受体临床试验中的临床试验.固体瘤是一种固体瘤.瘤微环境是一个微环境.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

672
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K

相关实验视频

Last Updated: Jul 25, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

672
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K
  • 卡尔T细胞疗法对固体瘤有潜力,但克服瘤特异性障碍至关重要.
  • 工程和战略患者选择方面的进步对于治疗成功至关重要.
  • 目前正在进行的临床试验将为多种癌症类型的疗效和安全提供关键数据.